Results 111 to 120 of about 70,369 (254)

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

open access: yesFrontiers in Oncology
PurposeThe National Cancer Institute’s Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) randomized phase 2 clinical trial assessed the utility of applying tumor DNA sequencing to treatment selection.
Yvonne A. Evrard   +24 more
doaj   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou   +4 more
wiley   +1 more source

Cellular Morphometric Analysis (CellMorph)—a comprehensive imaging‐based tool for quantifying cellular phenotype heterogeneity and dynamics across biological processes

open access: yesThe FEBS Journal, EarlyView.
CellMorph is a groundbreaking tool that allows researchers to analyze multiple features from single cells, including cell size and shape, cytosolic staining and subcellular texture, nuclear staining, and morphometry. By evaluating images from both bright‐field and fluorescence microscopy, it also tracks changes in living cells during key processes such
Henrique Quaiato de Oliveira   +16 more
wiley   +1 more source

Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.

open access: yes, 2004
Successful management of a heavily pretreated 58-year-old woman with metastatic esthesioneuoblastoma using temozolomide is reported. There is no standard treatment of this tumors with extra- and intracranial manifestations.
Wick, W   +4 more
core   +1 more source

Can Response Outcomes Predict Survival in Paediatric Patients Receiving Treatment for Relapsed and Refractory Rhabdomyosarcoma? Results From the Living‐REFoRMS Systematic Review

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 997-1004, 15 August 2026.
Although existing research suggests a limited relationship between survival outcomes and radiological response rates in children with newly diagnosed rhabdomyosarcoma, there is little evidence in the relapsed/refractory setting. Using aggregate data collected from the Living‐REFoRMS dataset of early‐phase trials, the authors established that ...
Preethi Muthukumar   +4 more
wiley   +1 more source

Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy

open access: yes, 2018
Jicai Zhang, Xiang Xiao, Jianming Zhu, Ziyun Gao, Xianliang Lai, Xingen Zhu, Guohua Mao Department of Neurosurgery, Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China Purpose: Glioblastoma multiforme (GBM) is the most common ...
Lai X   +6 more
core  

The economics of temozolomide in brain cancer.

open access: yes, 2007
For 30 years, nitrosourea was the only adjuvant treatment available for aggressive glioma patients, despite its severe side effects; and, therefore, radiotherapy was often the therapy of choice.
Crott, Ralph
core   +1 more source

Feasibility and Safety of High‐Dose Proton Re‐Irradiation in Recurrent Pediatric Central Nervous System Tumors: A Single‐Institution Retrospective Study

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Purpose Pediatric central nervous system (CNS) tumors often recur despite multimodality therapy. Although re‐irradiation (re‐RT) has historically been limited by concerns for severe late toxicities, modern techniques have renewed interest in this approach. Proton therapy provides dosimetric advantages that may enable curative re‐treatment with
Jin‐Ho Song   +15 more
wiley   +1 more source

Radiolabeled Angiopep‐2 Peptide Vector as a Preclinical Platform for Blood–Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice

open access: yesJournal of Peptide Science, Volume 32, Issue 7, July 2026.
The developed DOTA‐Angiopep‐2 conjugate was well tolerated in glioma cells and enabled high‐yield radiolabeling with 177Lu and 161Tb. The 161Tb conjugate showed brain delivery with predominantly renal clearance, supporting a stable radiotheranostic platform for BBB‐targeted glioma therapy and SPECT imaging.
Evgenia Fotou   +10 more
wiley   +1 more source

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer

open access: yesPigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy